Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients
10.1128/mbio.03404-22
Clin Endocrinol (Oxf) 84:851857 Semin MF, Veyse F, Ozer O, Simin R, Nedim K (2008) Serum LC in non-obese PCOS
The results showed no toxicities or serious adverse events.[ref] Synthetic thymosin beta 4: A phase I safety trial using synthetic thymosin beta 4 at doses from 42 to 1260 mg for 14 days showed no toxicity or serious adverse events.[ref] Human clinical trials for specific conditions: Venous ulcers: Wounds that dont heal, such as venous ulcers, are a significant problem in older patients with limited mobility
The process is quick and typically causes minimal discomfort
A total of 71 eligible studies, comprising 7360 CRC cases and 15982 controls, were included